Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
image source: pexels
The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy
The team at the Infectious Diseases Institute, Kampala
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.
RT @UNITAID: On #InternationalWomensDay, 8 March, Unitaid remains committed to addressing barriers to improve the lives and health of women in resource-constrained settings.
Discover how Unitaid is bridging the gender divide through access to life-saving innovations: https://t.co/o2mhyMNqbohttps://t.co/HiqKLimxNK
2 weeks 4 days ago
Laura Else from @LivUniISMIB will be presenting a poster at #CROI2023 today at 14 30 entitled Plasma & urine PK of #dolutegravir and #tenofovir to aid point-of-care testing. Stop by poster 527 to find out more
RT @UNITAID: In sub-Saharan Africa, over 1 in 5 HIV-infected pregnant women are diagnosed in late pregnancy each year. @UoLDolphin2 investigates factors that influence late antenatal initiation and the adherence to and retention in combination antiretroviral therapy programmes in pregnancy. https://t.co/gds9CbxJGZ
4 months 4 weeks ago
RT @CatrionaWaitt: @UoLDolphin2 consortium meeting hosted by @livuninews. We've shown that it is possible to do policy - changing research with women in late pregnancy, and have built a strong, international multi disciplinary team. Great final discussion on the next steps. I am excited! @UNITAIDhttps://t.co/LXi6eASMi0
4 months 4 weeks ago
The D2 Consortium
The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.